Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.78
FOLD's Cash-to-Debt is ranked lower than
72% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. FOLD: 1.78 )
Ranked among companies with meaningful Cash-to-Debt only.
FOLD' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.78  Med: 48.48 Max: No Debt
Current: 1.78
Equity-to-Asset 0.31
FOLD's Equity-to-Asset is ranked lower than
81% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. FOLD: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
FOLD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.47 Max: 0.84
Current: 0.31
0.28
0.84
Piotroski F-Score: 4
Altman Z-Score: -0.65
Beneish M-Score: 25.53
WACC vs ROIC
13.87%
-105.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -2091.64
FOLD's Operating Margin % is ranked lower than
87% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. FOLD: -2091.64 )
Ranked among companies with meaningful Operating Margin % only.
FOLD' s Operating Margin % Range Over the Past 10 Years
Min: -17680.72  Med: -2567.54 Max: -11.42
Current: -2091.64
-17680.72
-11.42
Net Margin % -2315.58
FOLD's Net Margin % is ranked lower than
88% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. FOLD: -2315.58 )
Ranked among companies with meaningful Net Margin % only.
FOLD' s Net Margin % Range Over the Past 10 Years
Min: -16427.82  Med: -2307.57 Max: -10.2
Current: -2315.58
-16427.82
-10.2
ROE % -63.91
FOLD's ROE % is ranked lower than
65% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. FOLD: -63.91 )
Ranked among companies with meaningful ROE % only.
FOLD' s ROE % Range Over the Past 10 Years
Min: -322.07  Med: -81.22 Max: -9.19
Current: -63.91
-322.07
-9.19
ROA % -22.36
FOLD's ROA % is ranked higher than
57% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. FOLD: -22.36 )
Ranked among companies with meaningful ROA % only.
FOLD' s ROA % Range Over the Past 10 Years
Min: -55.51  Med: -38.58 Max: -6.13
Current: -22.36
-55.51
-6.13
ROC (Joel Greenblatt) % -2133.89
FOLD's ROC (Joel Greenblatt) % is ranked lower than
72% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. FOLD: -2133.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FOLD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2904.44  Med: -1492.62 Max: -134.99
Current: -2133.89
-2904.44
-134.99
3-Year Revenue Growth Rate 74.20
FOLD's 3-Year Revenue Growth Rate is ranked higher than
92% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. FOLD: 74.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
FOLD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -59.1 Max: 74.2
Current: 74.2
0
74.2
3-Year EBITDA Growth Rate 6.60
FOLD's 3-Year EBITDA Growth Rate is ranked higher than
57% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. FOLD: 6.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
FOLD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -85.6  Med: -12.95 Max: 81.7
Current: 6.6
-85.6
81.7
3-Year EPS without NRI Growth Rate 8.70
FOLD's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. FOLD: 8.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
FOLD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -85.2  Med: -12.15 Max: 54.5
Current: 8.7
-85.2
54.5
» FOLD's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

FOLD Guru Trades in Q2 2016

Paul Tudor Jones 72,981 sh (+330.57%)
RS Investment Management 3,429,187 sh (-2.79%)
» More
Q3 2016

FOLD Guru Trades in Q3 2016

Jim Simons 196,400 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2016

FOLD Guru Trades in Q4 2016

Paul Tudor Jones 51,290 sh (New)
Jim Simons Sold Out
» More
Q1 2017

FOLD Guru Trades in Q1 2017

Steven Cohen 3,000,500 sh (New)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:GNFTF, NAS:CHRS, NAS:INSM, NAS:DERM, NAS:EPZM, NAS:XNCR, NAS:LOXO, OTCPK:PFSCF, NYSE:EBS, OTCPK:PHMMF, NAS:XLRN, NAS:AIMT, NAS:FWP, NAS:ZIOP, NAS:INVA, NAS:GBT, NAS:RGEN, NAS:INSY, NAS:AKAO, NAS:ASND » details
Traded in other countries:AM6.Germany,
Headquarter Location:USA
Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines for orphan diseases.

Amicus Therapeutics Inc is a global biotechnology company that aims to treat rare and orphan diseases. The company's strategy focuses on global capacity with an international infrastructure, late-stage product acquisition, and biologics manufacturing. Amicus leverages its pharmacological technology to develop treatments for human genetic diseases by targeting mutated proteins. The company utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products.

Top Ranked Articles about Amicus Therapeutics Inc

Amicus Therapeutics to Present at Two Upcoming Investor Conferences
Amicus Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in France
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Italy

Ministry of Health Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease

CRANBURY, N.J. and MILAN, Italy, March 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Italy following the final publication of reimbursement guidelines by the Ministry of Health (Ministero della Salute). Galafold is now reimbursed in Italy as a therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation.
"The commercial launch of Galafold in Italy is a significant milestone for the Fabry community,” stated John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. “All Fabry patients in Italy 16 years and older who have an amenable mutation will now have access to the first oral treatment as well as the first precision medicine for their Fabry disease. We believe that our successful pricing and reimbursement in Italy is a testament to the significant value of our oral precision medicine, and reflects our growing momentum with the country-by-country processes to launch Galafold throughout the EU.” Fabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A), which is the result of mutations in the GLA gene. As a precision medicine, Galafold is designed to restore alpha-Gal A activity in patients who have amenable mutations (an estimated 35% to 50% of the Fabry population). Dr. Iacopo Olivotto, manager of the Cardiomyopathy Unit of the Careggi Hospital in Florence, center for Fabry disease stated, “As an active site for the ATTRACT study, we are particularly pleased that Galafold will be available for Fabry patients in Italy. When there are more treatments available on the market for a rare disease, this automatically leads to an increase in the attention given to the disease and awareness surrounding it. Fabry disease is a virtuous example of how targeted treatments, based on a solid rationale, may improve treatment outcomes for patients” “Every time a new treatment opportunity is added to those available it is a day of celebration for patients,” said Stefania Tobaldini, President of the Associazione Italiana Anderson Fabry Onlus (AIAF). “Today our patient association is particularly grateful to scientific research as a new opportunity for treatment is available for the first time via oral administration. As of tomorrow, there will be a new task for the specialists who are following us on our complex paths to diagnosis and treatment; that of informing us and accompanying us in the exploration of Galafold as a new treatment option in Italy for patients with Fabry disease who have an amenable mutation.” The European Commission granted full approval for Galafold on May 30, 2016, as a first line therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. About Galafold™ and Amenable Mutations
Galafold™ (migalastat) is a first-in-class chaperone therapy approved in the EU as a monotherapy for Fabry disease in patients with amenable mutations. Galafold works by stabilizing the body’s own dysfunctional enzyme, so it can clear the accumulation of disease substrate in patients who have amenable mutations.  A proprietary in vitro assay (Galafold Amenability Assay) was used to classify more than 800 known GLA mutations as “amenable” or “not amenable” to treatment with Galafold. The current EU label includes 313 GLA mutations that have been identified and determined to be amenable based on the Galafold Amenability Assay, which represent between 35% and 50% of the currently diagnosed Fabry population. Healthcare providers in the EU may access the website www.galafoldamenabilitytable.com to quickly and accurately identify which mutations are categorized as “amenable” or “not amenable” to Galafold. Amicus expects to submit updates to the label as additional GLA mutations are identified and tested in the Galafold Amenability Assay. Important Safety Information
Treatment with GALAFOLD should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease. GALAFOLD is not recommended for use in patients with a nonamenable mutation. GALAFOLD is not intended for concomitant use with enzyme replacement therapy.GALAFOLD is not recommended for use in patients with Fabry disease who have severe renal impairment (<30 mL/min/1.73 m2). The safety and efficacy of GALAFOLD in children 0–15 years of age have not yet been established.No dosage adjustments are required in patients with hepatic impairment or in the elderly population.There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse.While taking GALAFOLD, effective birth control should be used. It is not known whether GALAFOLD is excreted in human milk.Contraindications to GALAFOLD include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION.It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on GALAFOLD or switched to GALAFOLD.OVERDOSE: General medical care is recommended in the case of GALAFOLD overdose.The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received GALAFOLD. For a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS.Call your doctor for medical advice about side effects.    For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu. About Fabry Disease
Fabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A), which is the result of mutations in the GLA gene. The primary biological function of alpha-Gal A is to degrade specific lipids in lysosomes, including globotriaosylceramide (referred to here as GL-3 and also known as Gb3). Lipids that can be degraded by the action of alpha-Gal A are called "substrates" of the enzyme. Reduced or absent levels of alpha-Gal A activity lead to the accumulation of GL-3 in the affected tissues, including the central nervous system, heart, kidneys, and skin. Progressive accumulation of GL-3 is believed to lead to the morbidity and mortality of Fabry disease, including pain, kidney failure, heart disease, and stroke. The symptoms can be severe, differ from patient to patient, and begin at an early age. All Fabry disease is progressive and may lead to organ damage regardless of the time of symptom onset. About Amicus Therapeutics
Amicus Therapeutics (NASDAQ:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases. Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, financing plans, and the projected cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and the potential that we will need additional funding to complete all of our studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2016. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof. FOLD–G
CONTACTS:

Investors/Media:
Amicus Therapeutics
Sara Pellegrino
Senior Director, Investor Relations
[email protected]
(609) 662-5044

Media:
MWW PR
Sid Dinsay
[email protected]
(646) 381-9017

Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.56
FOLD's PB Ratio is ranked higher than
61% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. FOLD: 3.56 )
Ranked among companies with meaningful PB Ratio only.
FOLD' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.22 Max: 14.52
Current: 3.56
0.87
14.52
PS Ratio 121.57
FOLD's PS Ratio is ranked lower than
91% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. FOLD: 121.57 )
Ranked among companies with meaningful PS Ratio only.
FOLD' s PS Ratio Range Over the Past 10 Years
Min: 0.85  Med: 33.48 Max: 4540
Current: 121.57
0.85
4540
EV-to-EBIT -4.81
FOLD's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. FOLD: -4.81 )
Ranked among companies with meaningful EV-to-EBIT only.
FOLD' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.3  Med: -2.6 Max: 2.1
Current: -4.81
-16.3
2.1
EV-to-EBITDA -4.87
FOLD's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. FOLD: -4.87 )
Ranked among companies with meaningful EV-to-EBITDA only.
FOLD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.6  Med: -2.8 Max: 4.1
Current: -4.87
-16.6
4.1
Current Ratio 2.70
FOLD's Current Ratio is ranked lower than
61% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. FOLD: 2.70 )
Ranked among companies with meaningful Current Ratio only.
FOLD' s Current Ratio Range Over the Past 10 Years
Min: 2.59  Med: 7.42 Max: 21.6
Current: 2.7
2.59
21.6
Quick Ratio 2.67
FOLD's Quick Ratio is ranked lower than
58% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. FOLD: 2.67 )
Ranked among companies with meaningful Quick Ratio only.
FOLD' s Quick Ratio Range Over the Past 10 Years
Min: 2.55  Med: 7.42 Max: 21.6
Current: 2.67
2.55
21.6
Days Inventory 479.36
FOLD's Days Inventory is ranked lower than
97% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. FOLD: 479.36 )
Ranked among companies with meaningful Days Inventory only.
FOLD' s Days Inventory Range Over the Past 10 Years
Min: 479.36  Med: 748.4 Max: 748.4
Current: 479.36
479.36
748.4
Days Sales Outstanding 74.98
FOLD's Days Sales Outstanding is ranked lower than
70% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. FOLD: 74.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
FOLD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.94  Med: 90.94 Max: 1088.97
Current: 74.98
63.94
1088.97
Days Payable 2.00
FOLD's Days Payable is ranked lower than
89% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. FOLD: 2.00 )
Ranked among companies with meaningful Days Payable only.
FOLD' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 5654.65 Max: 5654.65
Current: 2
2
5654.65

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -30.40
FOLD's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. FOLD: -30.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FOLD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -317.5  Med: -33.25 Max: -15.3
Current: -30.4
-317.5
-15.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 3.71
FOLD's Price-to-Median-PS-Value is ranked lower than
96% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. FOLD: 3.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FOLD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 0.55 Max: 108.85
Current: 3.71
0.03
108.85
Earnings Yield (Greenblatt) % -20.87
FOLD's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. FOLD: -20.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FOLD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -20.87  Med: 98.9 Max: 913.7
Current: -20.87
-20.87
913.7

More Statistics

Revenue (TTM) (Mil) $9.13
EPS (TTM) $ -1.54
Beta2.02
Short Percentage of Float34.98%
52-Week Range $4.41 - 9.61
Shares Outstanding (Mil)142.92
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
Amicus Therapeutics to Present at Two Upcoming Investor Conferences May 10 2017 
Amicus Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 May 02 2017 
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in France May 02 2017 
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day Apr 06 2017 
Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study Apr 03 2017 
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Italy Mar 08 2017 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Amicus Therapeutics, Inc. of Pende Oct 12 2015 
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 

More From Other Websites
Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa... May 19 2017
Today's Research Reports on Biotech Stocks to Watch: Exelixis and Amicus Therapeutics May 18 2017
Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2... May 15 2017
Edited Transcript of FOLD earnings conference call or presentation 9-May-17 12:30pm GMT May 10 2017
Amicus Therapeutics to Present at Two Upcoming Investor Conferences May 10 2017
ETFs with exposure to Amicus Therapeutics, Inc. : May 9, 2017 May 09 2017
Amicus Therapeutics reports 1Q loss May 09 2017
Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call May 09 2017
Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates May 09 2017
Amicus Therapeutics, Inc. – Value Analysis (NASDAQ:FOLD) : May 8, 2017 May 08 2017
Amicus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FOLD-US : May 5,... May 05 2017
Amicus Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 May 02 2017
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in France May 02 2017
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day Apr 06 2017
Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study Apr 03 2017
Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics Mar 17 2017
Are These 2 Biotechs Diamonds in the Rough? Mar 16 2017
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Italy Mar 08 2017
Harry Boxer’s six biotechnology stocks to watch Mar 07 2017
Four biotech stocks surging on optimism about drug trials, product launches Mar 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)